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Abstract
Research efforts in the area of palaeopathology have been seen as an avenue to improve our understanding of the
pathogenesis of cancer. Answers to questions of whether dinosaurs had cancer, or if cancer plagued ancient civiliza-
tions, have captured the imagination as well as the popular media. Evidence for dinosaurian cancer may indicate that
cancer may have been with us from the dawn of time. Ancient recorded history suggests that past civilizations at-
tempted to fight cancerwith a variety of interventions.When contemplating the issuewhy a generalized cure for cancer
has not been found, itmight prove useful to reflect on the relatively limited time that this issue has been an agenda item
of governmental attention aswell as continued introduction of an every evolvingmyriad ofmanmade carcinogens rela-
tive to the total time cancer has been present on planet Earth. This article reflects on the history of cancer and the
progress made following the initiation of the “era of cancer chemotherapy.”
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Perspective
Evidence from Dinosaurs (250 to 65 Million Years Ago)
Unraveling the history of cancer may provide insights and improve
our understanding of the etiology, pathogenesis, and intervention of this
disease. While it had been thought that there was generally ample evi-
dence that cancer was a normal population phenomenon in dinosaurs,
doubts still lingered as conclusive evidence was lacking. Earth history is
divided into aeons, eras, and periods. Dinosaurs and other prehistoric
reptiles roamed the Earth during theMesozoic era for about 185million
years, which lasted from 250 to 65million years ago. This era contained
three periods called the Triassic, Jurassic, and Cretaceous.
Recently, metastatic cancer and osteomas (in mosasaurs) were re-
ported (Rothschild BM,Witzke BJ, andHershkovitz I [1999].Metasta-
tic cancer in the Jurassic. Lancet 354 (9176), 398.). Even more recently,
researchers undertook an epidemiological investigation of tumors in
dinosaurs (Rothschild BM, Tanke DH, Helbling M 2nd, and Martin
LD [2003]. Epidemiologic study of tumors in dinosaurs. Naturwis-
senschaften 90 (11), 495–500). These investigators used computed
tomography for fluoroscopically screening more than 10,000 specimens
of dinosaur vertebrae for evidence of tumors. Of the specimens exam-
ined, investigators reported tumors in bones of Cretaceous hadrosaurs
(duck-billed dinosaurs). In this species, maximum cancer susceptibility
was approximately 3% of bones examined, which showed lumps by
imaging identified as various types of tumors including hemangiomas,
metastatic cancer, desmoplastic fibroma, and osteoblastoma. The famil-
ial pattern found seemed to reflect a genetic propensity or, alternatively,
the result of environmental mutagens because these dinosaurs likely ate
foliage of conifers rich in carcinogenic tannins, phenols, and resins.
Taking into account the limitations of the diagnostic tools used to
study remains, there is an agreement that cancer in dinosaurs is rel-
atively scarce. Age at death, diet, and environmental factors may have
a significant influence on the incidence of these cancers.
Evidence from Ancient Civilizations (Egyptian,
Greek, and Roman)
A recent overview of the literature investigating the presence of cancer
in ancient civilizations has been published (David AR and Zimmerman
MR [2010]. Cancer: an old disease, a new disease or something in be-
tween? Nat Rev Cancer 10, 728–733). Evidence of cancer in humans
has been uncovered in the earliest medical records found left by the
ancient Egyptians (3000-800 BC). Evidence consists of hieroglyphic
inscriptions along with papyri writings noting both benign and malig-
nant tumors. Egyptian culture allowed for working with human bodies
as evidenced by the mummification of the dead. The first histological
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confirmation of cancer in an Egyptian mummy revealed that cancer
was indeed present in ancient times (Zimmerman MR [1977]. An ex-
perimental study of mummification pertinent to the antiquity of can-
cer. Cancer 40, 1358–1362). In this report, Zimmerman diagnosed
the presence of rectal cancer in an unnamed mummy who had lived
in the Dakhleh Oasis during the Ptolemaic period (CE 200–400). The
fact that palaeopathology has shown that cancer is present in ancient
remains of Egyptians necessitated the need for the ancients to counter
attack this disease. Deciphered papyri from around 1500 BC contain
descriptions of cancer along with surgical intervention and treatments.
Evidence for the use of surgical removal of superficial tumors has been
found during this time.Deep-seated tumors were treated using different
prescriptions including ears of pigs and other parts of animals and fish
in such dispensions as poultices, ointments, and enemas. Thus, ancient
Egyptian physicians treated patients for several forms of cancer, and their
documents have provided both evidence of the disease along with the
treatments administered at the time. Egyptians were considered the
“fathers of pharmacology” as some treatments used were believed to
be “magical” but were, in fact, true therapeutic remedies.
An interesting phenomenon has arisen during the course of multi-
year studies related to the rarity of cancer in antiquity. This is of interest
especially when considering that hundreds of Egyptian mummies and
more than 10,000 dinosaur bones were evaluated. In contrast, the rate
of cancer incidence has dramatically increased since the Industrial Revo-
lution. The rarity of cancer in antiquity has been attributed to the lack
of pollution and changes in diet and lifestyle, and most recent findings
suggest that cancer may be a manmade disease (Nat Rev Cancer 10,
728–733). Thus, while a lack of adequate techniques for disease diag-
nosis and detection may partially explain the overall lack of cancer
found during the millennia, the current cancer trends are now primarily
associated with carcinogens in our modern industrialized society (Nat
Rev Cancer 10, 728–733). Whether this hypothesis is indeed the case,
what is clear from ancient Egyptian and Greek writings along with in-
formation accumulated throughout the millennia is that improved un-
derstanding of the biological basis for the disease as well as improved
cancer treatments is needed.
Overall Cancer Perspective
To put the historical findings into a more modern perspective, in
more than 3500 years of attempting to treat cancers effectively, the
concept of cancer chemotherapy was initiated only relatively recently
in the 1940s with the introduction of nitrogen mustards and folic acid.
These initial discoveries using poisonous chemicals for the treatment of
tumors were amajormedical advance as progress rapidly ensued, leading
to improvements in many cancer death rates. Moreover, the potential
and realities of targeted anticancer therapies have more recently emerged
some 50 to 70 years later. However, much work remains as cancer con-
tinues to be a major worldwide health problem, and progress in curing
patients with metastatic cancer remains elusive.
In an effort to continue to advance treatments against cancers, Neo-
plasia continues to serve as a major conduit for the dissemination of
relevant and timely information. Neoplasia has published numerous
significant articles covering broad areas of research including cell and
tumor biology, imaging, genetics, experimental therapeutics, and clini-
cal investigations (Table 1). Neoplasia provides its readership with a
broad scope related to many novel and diverse discoveries. The imme-
diate availability of Neoplasia articles to the worldwide clinical cancer
research community is a key and unique feature of Neoplasia, and
our primary goal is to allow open access of all articles at the time of
publication through PubMed Central. This feature provides authors’
research findings to the largest possible readership, thereby ensuring
that articles published in Neoplasia will have the opportunity to make
a significant impact. Finally, it has been a pleasure to serve the cancer
research community as editor this past year, and along with my editorial
board, I thank the scientific groups who have published with us and
take this as the highest form of honor.
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